Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).

Authors:
Terpos E; Musto P; Engelhardt M; Delforge M; Cook G and 16 more

Journal:
Leukemia

Publication Year: 2023

DOI:
10.1038/s41375-023-01920-1

PMCID:
PMC10157596

PMID:
37142661

Journal Information

Full Title: Leukemia

Abbreviation: Leukemia

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests Evangelos Terpos declares honoraria for advisory boards or lectures from Amgen, Astra/Zeneca, Bristol Myers Squibb, Eusa Pharma, GSK, Integris Pharma, Janssen, Pfizer, Sanofi and Takeda; research support (to institution) from Amgen, GSK, Janssen, Sanofi and Takeda; travel grants from Amgen, Eusa Pharma and Takeda. Pellegrino Musto declares honoraria for advisory boards or lectures from Celgene, Janssen-Cilag, Takeda, Amgen, BMS, Sanofi, Abbvie, Pfizer, Seattle Genetics and research support from Amgen, Sanofi. FG has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, and GlaxoSmithKline; has served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, Roche, Adaptive Biotechnologies, Oncopeptides, bluebird bio, and Pfizer. NWCJD has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis, Cellectis and BMS, and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, and Adaptive, all paid to institution. FS has received Grants from Celgene, Janssen, Oncopeptides, Sanofi, GSK, Targovax, Honoraria from Amgen, BMS, Takeda, Abbvie, Janssen, Novartis, SkyliteDX, Oncopeptides, Sanofi, Pfizer, Daiki-Sankyo, GSK, and Honoraria from participation in advisory boards for Abbvie, GSK, Celgene, Takeda, Janssen, Oncopeptides, Sanofi, BMS. CC declares Advisory board e/o speaker for Abbvie, AMGEN, Astellas, Beigene, BMS, Glycomimetics, GSK, Immunogen, Janssen, Jazz, Karyopharm, Menarini, Oncopeptides, Pfizer, Sanofi, Servier, Stemline, Takeda. Roman Hajek has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. PM declares honoraria and advisory boards from janssen, celgene, takeda, amgen, abbvie, Sanofi. Hermann Einsele declares Consulting or Advisory Role for BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis, Research Funding from BMS/Celgene, Janssen, Amgen, GSK, Sanofi, Honoraria from BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis, and Travel Support from BMS/Celgene, Janssen, Amgen, Takeda, Novartis, Sanofi. JS-M declares advisory boards and consulting services, on behalf of my Institution, for Abbvie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, and SecuraBio. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GlaxoSmithKline; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and Mundipharma. MAD declares honoraria from participation in Advisory Boards from Amgen, Takeda, BMS, Janssen, Beigene, Sanofi. PS declares research support from Amgen, BMS, Janssen, Sanofi, participation in Advisory Boards for Amgen, BMS, Janssen, Sanofi, Pfizer, Seagen, Karyopharm, Oncopeptides. HL declares research support from Amgen, Sanofi and honoraria for advisory boards/lectures from Celgene-BMS, Janssen-Cilag, Takeda, Amgen, Sanofi, Seattle Genetics, AbbVie, Pfizer, Oncopeptides. All other authors declare no conflicts of interest related to this paper."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025